Physician profile
Jonathan S Lowman
NPI 1699748061
$9,471.34
in general payments reported to CMS, 2019-2025
31 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,747 · 2020: $131 · 2022: $238 · 2023: $1,575 · 2024: $1,496 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,355.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $4,582.50 | 2019 | |
| Novo Nordisk INC | $739.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $668.45 | 2019-2025 | |
| Lilly USA, LLC | $566.90 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $544.66 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $451.11 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $221.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $211.32 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.10 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $190.12 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $148.06 | 2024-2025 | |
| Astellas Pharma US INC | $135.33 | 2020-2025 | Veozah |
| Amgen INC. | $127.82 | 2020-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $95.08 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $80.83 | 2022-2023 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $77.80 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $62.89 | 2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $44.30 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.29 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $39.41 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.74 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $34.16 | 2020-2023 | Belsomra |
| Sumitomo Pharma America, INC. | $24.68 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $24.10 | 2025 | Symbravo |
| Xeris Pharmaceuticals, INC. | $23.79 | 2025 | Gvoke Hypopen |
| Tolmar, INC. | $17.85 | 2025 | Jatenzo |
| Mylan Specialty L.P. | $17.69 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $17.61 | 2024 | Zoryve |
| Dynavax Technologies Corporation | $16.43 | 2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $15.08 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.66 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.